239 related articles for article (PubMed ID: 34274531)
1. Dually targeted bioinspired nanovesicle delays advanced prostate cancer tumour growth in vivo.
Ma G; Severic M; Barker M; Pereira S; Ruiz A; Cheung CCL; Al-Jamal WT
Acta Biomater; 2021 Oct; 134():559-575. PubMed ID: 34274531
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy.
Pereira S; Ma G; Na L; Hudoklin S; Kreft ME; Kostevsek N; Al-Jamal WT
Acta Biomater; 2022 Mar; 140():530-546. PubMed ID: 34954416
[TBL] [Abstract][Full Text] [Related]
3. Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design.
Pereira SGT; Hudoklin S; Kreft ME; Kostevsek N; Stuart MCA; Al-Jamal WT
Mol Pharm; 2019 Apr; 16(4):1573-1585. PubMed ID: 30802065
[TBL] [Abstract][Full Text] [Related]
4. Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo.
Severic M; Ma G; Pereira SGT; Ruiz A; Cheung CCL; Al-Jamal WT
J Control Release; 2021 Feb; 330():101-110. PubMed ID: 33333118
[TBL] [Abstract][Full Text] [Related]
5. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
[TBL] [Abstract][Full Text] [Related]
6. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
7. A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile.
Boinapally S; Ahn HH; Cheng B; Brummet M; Nam H; Gabrielson KL; Banerjee SR; Minn I; Pomper MG
Sci Rep; 2021 Mar; 11(1):7114. PubMed ID: 33782486
[TBL] [Abstract][Full Text] [Related]
8. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
11. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
Khan SR; Denmeade SR
Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
[TBL] [Abstract][Full Text] [Related]
12. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
[TBL] [Abstract][Full Text] [Related]
13.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
16. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
Horn T; Krönke M; Rauscher I; Haller B; Robu S; Wester HJ; Schottelius M; van Leeuwen FWB; van der Poel HG; Heck M; Gschwend JE; Weber W; Eiber M; Maurer T
Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843
[TBL] [Abstract][Full Text] [Related]
17. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
19. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
Nagesh PKB; Johnson NR; Boya VKN; Chowdhury P; Othman SF; Khalilzad-Sharghi V; Hafeez BB; Ganju A; Khan S; Behrman SW; Zafar N; Chauhan SC; Jaggi M; Yallapu MM
Colloids Surf B Biointerfaces; 2016 Aug; 144():8-20. PubMed ID: 27058278
[TBL] [Abstract][Full Text] [Related]
20. Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Horchani A; Oueslati R
Tunis Med; 2013 Jul; 91(7):458-63. PubMed ID: 24008878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
